What it does
Johnson & Johnson is a healthcare company that researches, develops, manufactures and sells prescription medicines and medical technologies. It is a holding company whose operating companies manage day-to-day operations in markets around the world. J. Duato is Chairman and Chief Executive Officer.
Its Innovative Medicine business sells prescription medicines in oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. Its oncology portfolio includes treatments for multiple myeloma, prostate cancer, lung cancer and bladder cancer. Its immunology medicines treat inflammatory conditions including psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. These medicines are supplied to retailers, wholesalers, distributors, hospitals and healthcare professionals.
Its MedTech business makes products used by clinicians in cardiovascular care, orthopaedics, surgery and vision. The cardiovascular portfolio includes tools for heart-rhythm disorders, circulatory support, vascular disease and stroke care. Surgery includes instruments, energy devices, stapling systems, wound-closure products, biosurgery products, digital technologies and robotic systems. Vision includes ACUVUE contact lenses and TECNIS intraocular lenses used in cataract and refractive procedures. These products are used principally by physicians, nurses, hospitals, eye-care professionals and clinics.
How it makes money
Johnson & Johnson earns revenue by selling prescription medicines through Innovative Medicine and medical products through MedTech. In FY2025, revenue was $94.2 billion; in Q3 2026, management reported sales of more than $25 billion.
Innovative Medicine generated $60.4 billion in FY2025, or 64.1% of revenue. Its largest therapeutic area was oncology, where 2025 sales were $25.4 billion. DARZALEX and DARZALEX FASPRO, treatments for multiple myeloma, were collectively the company’s largest product and accounted for approximately 15.0% of FY2025 revenue. STELARA was its second largest product, accounting for approximately 6.5%, and TREMFYA was third, accounting for approximately 5.5%. The company also sells medicines across immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism.
MedTech generated $33.8 billion in FY2025, or 35.9% of revenue. It sells products across cardiovascular care, orthopaedics, surgery and vision through wholesalers, hospitals and retailers. Its products support acute and elective procedures, including minimally invasive catheter-based cardiovascular procedures, joint reconstruction, open and robotic surgery, and corrective and surgical vision care.
Medicines are prescribed and supplied through healthcare channels, while MedTech revenue follows the purchase and use of products in clinical procedures and vision care. Many medicines were developed with strategic partners or licensed from other companies, and maintain active lifecycle-development programs. New products introduced within the past five years accounted for approximately 25% of 2025 sales.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Innovative Medicine | $60.4 billion | 64.1% | 6.03% |
| MedTech | $33.8 billion | 35.9% | 6.07% |
Customers and how it sells
Innovative Medicine distributes prescription medicines directly to retailers, wholesalers, distributors, hospitals and healthcare professionals. MedTech distributes products to wholesalers, hospitals and retailers; the products are used principally by physicians, nurses, hospitals, eye-care professionals and clinics.
Johnson & Johnson operates in virtually all countries, although the products sold, principal markets and distribution methods vary by country and culture. The United States generated $53.8 billion in FY2025 revenue, or 57.1% of the total. Europe generated $21.5 billion, or 22.9%; Asia-Pacific and Africa generated $14.0 billion, or 14.9%; and the Western Hemisphere excluding the United States generated $4.9 billion, or 5.18%.
Three wholesalers distributing products for both segments represented approximately 21.8%, 15.5% and 11.1% of total gross revenues in 2025. The company maintains a policy generally preventing direct delivery of most drugs to a location other than the customer’s billing location, subject to exceptions. The policy affects certain contract-pharmacy transactions involving 340B covered entities.
| Region | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| United States | $53.8 billion | 57.1% | 6.86% |
| Europe | $21.5 billion | 22.9% | 6.55% |
| Asia-Pacific, Africa | $14.0 billion | 14.9% | 3.22% |
| Western Hemisphere excluding U.S. | $4.9 billion | 5.18% | 3.42% |
Suppliers and costs
Raw materials essential to the business are generally available from multiple sources. The company states that, where exceptions exist, temporary unavailability would not likely have a material adverse effect on financial results. Its global supply chains and production and distribution processes are complex and subject to increasing regulatory requirements that may affect sourcing, supply and material pricing.
Research and development is a significant cost of maintaining and improving medicines, devices and processes. The company invested $14.7 billion in research and development in 2025. Manufacturing may also involve third parties; associated risks include reliance on those parties for regulatory compliance and quality assurance, limited inventory control, intellectual-property misappropriation, and potential termination or nonrenewal of manufacturing agreements.
DARZALEX has a specific licensing cost: Janssen Biotech holds an exclusive license to two Genmab patent families, with royalties ranging from 12% to 20% of total DARZALEX net sales. Royalty amounts to Genmab were approximately $2.4 billion in FY2025.
- Revenue$94.2B
- Cost of revenue−$30.3B
- Research and development−$14.7B
- Selling, general and administrative−$23.7B
- Other operating costs−−$7.0B
- Operating income$32.6B
Competitive position
Johnson & Johnson competes locally and globally in all of its product lines. Competition includes research to develop and improve products and processes, as well as competition after products reach the market. The company identifies continuing research investment, new and innovative products, and protection of its intellectual property as important to success.
Patent protection covers products, uses, formulations and manufacturing processes, but third parties challenge patents and seek to introduce generic and biosimilar versions of key pharmaceutical products before applicable patents expire. Biosimilar competition has reduced STELARA sales, and the company expects continued global biosimilar launches to continue negatively affecting that product’s sales. It also expects generic competition for OPSUMIT in 2026, which it says would likely significantly reduce future sales.
AbbVie is named in connection with IMBRUVICA, which is developed in collaboration and co-commercialized in the United States with Pharmacyclics LLC, an AbbVie company. Gilead is named in a reported preclinical comparison involving HCXT-2001 and ICOTYDE.
Our reading: Patent portfolios and licenses offer meaningful protection while they remain in force, but biosimilar and generic entry can materially weaken a medicine’s sales base, as shown by STELARA. Our reading: The breadth of medicines, devices and clinical-use products provides several areas for product development and competition, but it does not remove the need for continued research spending and intellectual-property protection.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| AbbVie | U.S. co-commercialization of IMBRUVICA | Medium |
| Gilead | preclinical comparison involving ICOTYDE | Low |
Growth opportunities
The company’s growth plans center on developing and launching medicines and medical technologies across its two segments. New products introduced within the past five years accounted for approximately 25% of 2025 sales, and the company invested $14.7 billion in research and development that year.
In Innovative Medicine, management said on the call that Q3 2026 operational sales grew 7.9%, with eight brands growing double digits. Management identified oncology, immunology and neuroscience as strategic areas. It said oncology grew by approximately 17% in Q3 and that its ambition is to become the number 1 oncology company by 2030, with projected sales exceeding $50 billion. Management also said it expects regulatory developments and data readouts for products including RYBREVANT FASPRO, INLEXZO and ICOTYDE.
In MedTech, management said Q3 2026 operational sales growth was 2.5%, below its expectations. It identified cardiovascular launches, including pulsed-field-ablation and intravascular-lithotripsy catheters, clinical evidence for Impella, and OTTAVA robotic surgery as areas not yet fully reflected in growth. Management said OTTAVA had received U.S. FDA de novo authorization, had its first commercial customer, and had an investigational device-exemption trial underway in inguinal hernia repair. It expects adoption and revenue contribution to build over time.
The company also intends to separate its Orthopaedics business. Management said on the call that it remains on track for a planned separation of DePuy Synthes by mid-2027 and is leaning toward a spin.
- $78.7BFY2021
- $80.0BFY2022
- $85.2BFY2023
- $88.8BFY2024
- $94.2BFY2025
Structural risks
-
Competition and innovation: The businesses operate in highly competitive product markets. Competition in research and the development and improvement of new and existing products is particularly significant, and substantial continuing research investment is required.
-
Loss of exclusivity: Third parties challenge patents and seek approval to market generic and biosimilar versions of key pharmaceutical products. The company expects further biosimilar launches to continue negatively affecting STELARA sales, and expects generic competition for OPSUMIT in 2026.
-
Healthcare pricing and reimbursement: Global Innovative Medicine and MedTech sales may be negatively affected by healthcare reforms and increasing pricing pressures. Government-established Medicare pricing, inflation rebates, Part D benefit redesign, payors and pharmacy benefit managers can affect pricing, access and market conditions.
-
Regulatory and product risk: Product safety, efficacy, manufacturing, advertising, labeling and safety reporting are regulated. Regulatory authorities can impose product withdrawals, recalls, seizures, civil or criminal sanctions, approval restrictions and other actions.
-
International operations: Operations outside the United States face risks from financial instability, restrictive policies, political and legal uncertainty, currency movements, geopolitical events, trade measures and restrictions on manufacturing or sales.
-
Orthopaedics separation: The planned separation may not be completed on the contemplated terms or timeline, may involve significant costs, and may not achieve the anticipated strategic or financial benefits.
Bottom line
Our reading
Our reading: Johnson & Johnson is a diversified healthcare business built around prescription medicines and clinician-used medical technologies, with Innovative Medicine supplying the larger share of FY2025 revenue. Our reading: Its product breadth, research spending, global distribution and intellectual-property portfolio support multiple development paths, while product-specific loss of exclusivity remains a material exposure. Our reading: Recent growth has been led by Innovative Medicine, while MedTech reported below-expectation Q3 growth and faces operational pressure in selected international markets.